Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 5/20 | 0.50 |
| ▸ | NOS1 | P29475 | 5/20 | 0.50 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499853 | 0.93 | NOS3 (0.48) | NOS3NOS1NOS2SNCAALDH1A1 | |
| SCHEMBL499453 | 0.92 | NOS3 (0.48) | NOS3NOS1NOS2SNCAALDH1A1 | |
| SCHEMBL499330 | 0.88 | NOS3 (0.42) | NOS3NOS1NOS2SNCAALDH1A1 | |
| SCHEMBL499331 | 0.88 | NOS3 (0.42) | NOS3NOS1NOS2SNCAALDH1A1 | |
| SCHEMBL499503 | 0.84 | LMNA (0.38) | NOS3NOS1NOS2SNCAALDH1A1 | |
| SCHEMBL499103 | 0.84 | NOS3 (0.49) | NOS3NOS1NOS2CHRM2HTR1A | |
| SCHEMBL499350 | 0.84 | NOS3 (0.50) | NOS3NOS1NOS2SNCAALDH1A1 | |
| SCHEMBL499158 | 0.84 | NOS3 (0.50) | NOS3NOS1NOS2SNCAALDH1A1 | |
| SCHEMBL499383 | 0.83 | NOS3 (0.42) | NOS3NOS1NOS2SNCAALDH1A1 | |
| SCHEMBL499382 | 0.83 | NOS3 (0.42) | NOS3NOS1NOS2SNCAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102143961-B | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON INC | 2014-11-05 | — | — | CN | disclosed |
| US-20140163016-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-06-12 | — | — | US | disclosed |
| US-20140163016-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-06-12 | — | — | US | disclosed |
| US-20140163016-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-06-12 | — | — | US | disclosed |
| US-8618286-B2 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-12-31 | — | — | US | disclosed |
| US-20120122855-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2012-05-17 | — | — | US | disclosed |
| US-20120122855-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2012-05-17 | — | — | US | disclosed |
| US-20120122855-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2012-05-17 | — | — | US | disclosed |
| US-8106043-B2 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| US-8106043-B2 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| CN-102143961-A | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON INC | 2011-08-03 | — | — | CN | disclosed |
| EP-2310386-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2011-04-20 | — | — | EP | disclosed |
| US-20100009975-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2010-01-14 | — | — | US | disclosed |
| US-20100009975-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2010-01-14 | — | — | US | disclosed |
| WO-2010000073-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010000073-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009975-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | NOS3 3/4885NOS1 2/4885NOS2 1/4885 |
| US-20120122855-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | NOS3 3/4885NOS1 2/4885NOS2 1/4885 |
| US-20140163016-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | NOS3 3/4885NOS1 2/4885NOS2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.